Roche Will Miss Goal of Filing RNAi Rx IND This Year, Tekmira Exec Says | GenomeWeb

Roche will not meet its previously disclosed goal of filing an investigational new drug application for an siRNA-based drug candidate in 2010, an official from partner Tekmira Pharmaceuticals disclosed last week.

As reported by Gene Silencing News in 2009, Roche had been expecting to file the IND on what would be its first RNAi drug sometime this year (GSN 10/1/2009).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.